Table of Contents
Building a biopharmaceutical company committed to...
Safe Harbor Statement
Amylin Pharmaceuticals, Inc.Uniquely Positioned to Build a Franchise in Metabolic Diseases
2002 Achievements
Corporate Strategy
Corporate Strategy
Corporate Strategy
SYMLIN™ (pramlintide acetate)Potential Complementary Therapy to Insulin
SYMLIN™ (pramlintide acetate) Unique Profile in Type 1 and Type 2 Diabetes
SYMLIN™ Regulatory Status
SYMLIN™ Market OpportunityUnited States
SYMLIN™ Market OpportunityUnited States
SYMLIN™ Commercial PlansUnited States
AC2993 (exenatide)Potential Treatment for Type 2 Diabetes
AC2993 Market OpportunityUnited States
AC2993 28-Day Profile in Type 2 DiabetesPotent Glucose-Lowering with No Weight Gain
AC2993 Global Collaboration with Eli Lilly and Company
AC2993 Program Update
AC2993 12-Week Profile in Type 2 DiabetesOpen-label Data Show Progressive Reductions in HbA1c
AC2993 LARGoal: Sustained-Release Treatment for Type 2 Diabetes
Corporate Strategy
Cardiovascular DiseaseBuilding on Our Strengths
ObesityBuilding on Our Strengths
Amylin Product Pipeline Summary
Management Experience and Expertise
Financial Overview
Milestones
Amylin Pharmaceuticals, Inc.Uniquely Positioned to Build a Franchise in Metabolic Diseases
|